Talphera (NASDAQ:TLPH) Trading Down 1.9% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) traded down 1.9% during mid-day trading on Wednesday . The company traded as low as $0.8030 and last traded at $0.8312. 77,131 shares were traded during trading, a decline of 59% from the average session volume of 190,092 shares. The stock had previously closed at $0.8470.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Talphera currently has an average rating of “Sell”.

Talphera Price Performance

The firm has a market capitalization of $40.17 million, a PE ratio of -2.17 and a beta of 0.56. The firm’s fifty day moving average is $0.82 and its two-hundred day moving average is $1.03.

Talphera (NASDAQ:TLPH) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. As a group, equities research analysts predict that Talphera, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity

In related news, insider Badri N. Dasu bought 35,000 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the completion of the purchase, the insider directly owned 76,230 shares in the company, valued at $61,746.30. The trade was a 84.89% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Vincent J. Angotti bought 213,310 shares of the company’s stock in a transaction on Friday, March 13th. The stock was bought at an average price of $0.59 per share, for a total transaction of $125,852.90. Following the completion of the purchase, the chief executive officer owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. The trade was a 36.31% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 433,674 shares of company stock valued at $304,348 in the last three months. 5.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC boosted its stake in Talphera by 3,224.0% in the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after acquiring an additional 29,500 shares during the last quarter. Virtu Financial LLC purchased a new position in Talphera in the third quarter valued at about $29,000. Persistent Asset Partners Ltd purchased a new position in Talphera in the fourth quarter valued at about $42,000. Mariner LLC boosted its stake in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after acquiring an additional 33,000 shares during the last quarter. Finally, Dauntless Investment Group LLC purchased a new position in Talphera in the third quarter valued at about $89,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.